100% Same
Salt CompositionEffectivenessStrength
with Substitute Medicine
Salt Composition in bothOur Recommendation
Antenoid 1mg Tablet 10s
Johnlee Pharmaceuticals Pvt. Ltd.
10+ trust this
WHO GMP Certified
WHO GMP
Certified
15 Days Easy
Returns
Long Expiry
(>8 Months)
WHO GMP
Certified
15 Days Easy
Returns
Long Expiry
(>8 Months)
Delivery by
Used In
Chronic hepatitis B virus (HBV) infection
Customers also bought
More About Baraclude 1mg Tablet
Benefits
In Chronic hepatitis B virus (HBV) infection In patients with chronic hepatitis B virus (HBV) infection, Baraclude 1mg Tablet works by preventing the HBV virus from multiplying in the body. It helps control the infection and makes the immune system work better. This lowers the chances of getting complications and improves the quality of life. This medicine is always taken in combination with other antiretroviral medicines. It is not a cure and should neither be used to prevent HBV infection. It is important that you take this medicine as prescribed, following the dosage recommended by your doctor. Taking all doses in the right amount at the right times greatly increases the effectiveness of the medicine.
Side Effects
The majority of side effects typically do not necessitate medical intervention. and disappear as your body adjusts to the medicine. Doctor consultation is advised if they persist or if you're worried about them.
How to use
Follow your doctor's guidance regarding the dose and duration of this medication. Ingest it without breaking or crushing. Do not chew, crush or break it. Baraclude 1mg Tablet is to be taken empty stomach.
How it works
Baraclude 1mg Tablet is an antiviral medication. It prevents the multiplication of virus in human cells. This stops the virus from producing new viruses and clears up your infection.
Consult your Doctor: Please consult your doctor regarding the safety of consuming alcohol with Baraclude 1mg Tablet . Experts have not found evidence of alcohol impairing the effectiveness of the medicine.
Seek medical advice from your doctor: Baraclude 1mg Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Doctor consultation is advised.
Seek medical advice from your doctor: Baraclude 1mg Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Not Safe: Baraclude 1mg Tablet may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Caution Advised: Baraclude 1mg Tablet should be used with caution in patients with kidney disease. Dose adjustment of Baraclude 1mg Tablet may be needed. Doctor consultation is advised.
Safe when prescribed by an expert: Baraclude 1mg Tablet is safe to use in patients with liver disease. No dose adjustment of Baraclude 1mg Tablet is recommended.
What if I forget to take it?
If a dose of Baraclude 1mg Tablet is missed, take it promptly. However, if your next dose is approaching, skip the missed dose and resume your regular schedule. Avoid doubling the dose.
Manufacturer Address
Bristol-Myers Squibb India Pvt. Ltd., The India Bulls Finance Centre, 6th Floor, Tower 1, Senapati Bapat Marg, Elphinstone (W), Mumbai - 400013
References
Acosta EP, Flexner C. Antiviral Agents (Nonretroviral). In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilmans: The Pharmacological Basis of Therapeutics. New York, New York: McGraw-Hill Medical; 2011. pp. 1616-617
Safrin S. Antiviral Agents. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. 11th ed. New Delhi, India: Tata McGraw Hill Education Private Limited; 2009. p. 869
Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. pp. 474-75
Entecavir. Uxbridge, Middlesex: Bristol-Myers Squibb Pharmaceuticals limited; 2006
Entecavir. Princeton, New Jersey: Bristol-Myers Squibb; 2005 (31 Mar. 2019)
Central Drugs Standard Control Organisation (CDSCO) (31 Mar. 2019)
CiplaMed. Entecavir (22 Jun. 2023)
Entecavir (22 Jun. 2023)
Disclaimer
PlatinumRx is dedicated to delivering dependable and trustworthy information to empower our customers. However, the information presented here is solely for general informational purposes and should not be utilized for diagnosing, preventing, or treating health issues. It is not intended to establish a doctor-patient relationship or serve as a substitute for professional medical advice.
Health Articles
